Compare Enveric Biosciences Inc (ENVB) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs General Motors Company — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while General Motors Company trades at $82.5 (market cap $71.06B). The key difference: General Motors Company is far larger — about 10621.8× Enveric Biosciences Inc's market cap, and General Motors Company pays a 0.89% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and General Motors Company for 83 Days on average.
| ENVB | GM | |
|---|---|---|
Market Cap | $6.69M | $71.06B |
Volume | 41,141 | 6,269,264 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $90.30 |
52-Week Low | $1.27 | $55.35 |
Typical Hold Time | 14 Days | 83 Days |
Enterprise Value | -$1.60M | $174.04B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
General Motors (GM) trades at $80.99, down 1.24% on the day, amid a broader market downturn and weak Q3 2026 vehicle sales. The stock shows a bearish technical signal, with key support at $80. Fundamentally, GM's revenue dipped to $185.02B in 2025 with a thin net margin of 1.05%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights competitive pressure from Toyota and a 5.5% decline in Q3 U.S. sales, driven by EV softness.
GM faces headwinds from declining market share and high debt levels, but analyst consensus remains bullish with a $102.08 price target, implying significant upside. Investment appeal hinges on execution amid industry shifts, while risks include rising borrowing costs and intense competition. Cash flow stability offers some cushion, but profitability recovery is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
